Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342251 | 0.81 | GABBR2 (0.36) | ACHEMAPTLMNASMN1; SMN2 | |
| SCHEMBL205612 | 0.72 | CHRNA7 (0.42) | ACHECHRNA7ALDH1A1STAT3TDP1 | |
| SCHEMBL16979038 | 0.67 | ESR1 (0.44) | ACHECHRNA7MAPTALDH1A1STAT3 | |
| SCHEMBL13628958 | 0.65 | CHRNA7 (0.37) | ACHECHRNA7ALDH1A1STAT3TDP1 | |
| SCHEMBL1101003 | 0.65 | ALDH1A1 (0.45) | ACHECHRNA7MAPTALDH1A1TDP1 | |
| SCHEMBL3989199 | 0.65 | ADRA2A (0.48) | ACHECHRNA7MAPTALDH1A1TDP1 | |
| SCHEMBL14183097 | 0.64 | CHRNA7 (0.39) | ACHECHRNA7ALDH1A1STAT3TDP1 | |
| P-Xylene SCHEMBL9064050 | 0.64 | CHRNA7 (0.39) | ACHECHRNA7ALDH1A1STAT3TDP1 | |
| SCHEMBL8609874 | 0.63 | CHRNA7 (0.42) | ACHECHRNA7MAPTALDH1A1STAT3 | |
| SCHEMBL3667006 | 0.63 | CYP1A2 (0.42) | ACHECHRNA7MAPTTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-1696959-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050215521-A1 | Modafinil combination therapy for improving sleep quality | SEPRACOR INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063248-A1 | MODAFINIL COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20030162754-A1 | Use of GABA and GABAB agonists | TUFTS UNIVERSITY | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215521-A1 | Modafinil combination therapy for improving sleep quality | HCRTR2, HCRTR1, MTNR1A | ACHE 1151/4885CHRNA7 157/4885MAPT 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.